vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v22i3.2576vsp-3223Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWСемейная гиперхолестеринемия у детей. Современное состояние проблемыFamilial Hypercholesterolemia in Children. The Current State of the Problemhttps://orcid.org/0000-0002-6662-3548СадыковаД. И.SadykovaDinara I.

Казань

Kazan

https://orcid.org/0000-0001-7327-7025СалаховаК. Р.SalakhovaKarina R.

Салахова Карина Равилевна - ординатор кафедры госпитальной педиатрии Казанского государственного медицинского университета.

420012, Казань, ул. Бутлерова, 49

Kazan

karina.salakh@mail.ruhttps://orcid.org/0000-0001-5576-5279ГалимоваЛ. Ф.GalimovaLiliya F.

Казань

Kazan

https://orcid.org/0000-0002-1732-7443СластниковаЕ. С.SlastnikovaEugeniya S.

Казань

Kazan

https://orcid.org/0000-0001-6667-7725ХалиуллинаЧ. Д.KhaliullinaChulpan D.

Казань

Kazan

Казанский государственный медицинский университет; Научно-исследовательская лаборатория «Генетика и клиника липидного обмена человека», Казанский федеральный университетРоссияKazan State Medical University; Research Laboratory “Genetics and Clinic of Human Lipid Metabolism”, Kazan Federal UniversityRussian FederationКазанский государственный медицинский университет; Научно-исследовательская лаборатория «Генетика и клиника липидного обмена человека», Казанский федеральный университет; Детская республиканская клиническая больницаРоссияKazan State Medical University; Research Laboratory “Genetics and Clinic of Human Lipid Metabolism”, Kazan Federal University; Children’s Republican Clinical HospitalKazanRussian FederationКазанский государственный медицинский университетРоссияKazan State Medical UniversityRussian Federation202308072023223231240Copyright © Садыкова Д.И., Салахова К.Р., Галимова Л.Ф., Сластникова Е.С., Халиуллина Ч.Д., 20232023Садыкова Д.И., Салахова К.Р., Галимова Л.Ф., Сластникова Е.С., Халиуллина Ч.Д.Sadykova D.I., Salakhova K.R., Galimova L.F., Slastnikova E.S., Khaliullina C.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/3223

Сердечно-сосудистые заболевания являются основной причиной инвалидизации и смертности населения по всему миру. Показатель сердечно-сосудистой смертности неуклонно растет даже на фоне масштабных профилактических мероприятий. Самым распространенным генетически обусловленным нарушением липидного обмена, которое служит основной причиной развития и прогрессирования заболеваний системы кровообращения, является семейная гиперхолестеринемия. Во всем мире насчитывается 6,8–8,5 млн детей c этой первичной дислипидемией. Ранняя (в детском возрасте) диагностика семейной гиперхолестеринемии важна для своевременного начала липидснижающей терапии с целью сокращения темпов прогрессирования атеросклероза и риска жизнеугрожающих сердечнососудистых событий. Для повышения эффективности этих мероприятий в экономически развитых странах внедряются новые программы скрининга, изучаются новые биомаркеры болезни, разрабатываются гиполипидемические препараты с новыми механизмами гиполипидемического действия.

Cardiovascular diseases are the leading cause of disability and mortality worldwide. Cardiovascular mortality rate is steadily increasing despite the large-scale preventive measures. Familial hypercholesterolemia is the most common genetically determined disorder of lipid metabolism as the major cause of blood circulatory system diseases development and progression. Worldwide, there are 6.8–8.5 million children with this primary dyslipidemia. Early (in childhood) diagnosis of familial hypercholesterolemia is crucial for the timely initiation of lipid-lowering therapy in order to reduce the atherosclerosis progression and the risk of life-threatening cardiovascular events. New screening programs have been implemented, new biomarkers of the disease have been studied, and lipid-lowering drugs with new mechanisms of hypolipidemic action have been developed to increase the efficacy of these activities in economically developed countries.

детисемейная гиперхолестеринемиядиагностикалипопротеиды низкой плотностидислипидемияперспективные направления исследованийchildrenfamilial hypercholesterolemiadiagnosticslow-density lipoproteinsdyslipidemiaadvanced research directionsРабота выполнена при финансовой поддержке Казанского государственного медицинского университета, грант Международного научного совета для молодых ученых (получатель — Салахова К.Р., 2022)The study was carried out with the financial support of Kazan State Medical University, grant from the International research board for young scientists (recipient — K.R. Salakhova, 2022)ReferencesCardiovascular diseases. In: World Health Organization: Official website. Available online: https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1. Accessed on April 12, 2023.Cardiovascular diseases. In: World Health Organization: Official website. Available online: https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1. Accessed on April 12, 2023.Маль Г.С., Смахтина А.М. Вторичная гиперлипидемия: определение, фенотипы и индуцирующие факторы // Международный журнал сердца и сосудистых заболеваний. — 2021. — Т. 9. — № 32. — С. 43–51. — doi: https://doi.org/10.24412/2311-16232021-32-43-51Mal GS, Smakhtina AM. Secondary hyperlipidemia: definition, phenotypes and inducing factors. International Heart and Vascular Disease Journal. 2021;9(32):43-51. (In Russ). doi: https://doi.org/10.24412/2311-1623-2021-32-43-51Thongtang N, Sukmawan R, Llanes EJB, Lee ZV. Dyslipidemia management for primary prevention of cardiovascular events: Best in-clinic practices. Preventive Medicine Reports. 2022;27:a101819. doi: https://doi.org/10.1016/j.pmedr.2022.101819Thongtang N, Sukmawan R, Llanes EJB, Lee ZV. Dyslipidemia management for primary prevention of cardiovascular events: Best in-clinic practices. Preventive Medicine Reports. 2022;27:a101819. doi: https://doi.org/10.1016/j.pmedr.2022.101819Концевая А.В., Баланова Ю.А., Имаева А.Э. и др. Экономический ущерб от гиперхолестеринемии на популяционном уровне в Российской Федерации // Рациональная фармакотерапия в кардиологии. — 2018. — Т. 14. — № 3. — С. 393–401. — doi: https://doi.org/10.20996/1819-6446-2018-14-3-393401Kontsevaya AV, Balanova YA, Imaeva AE, et al. Economic burden of hypercholesterolemia in the Russian Federation. Rational pharmacotherapy in cardiology. 2018;14(3):393–401. doi: https://doi.org/10.20996/1819-6446-2018-14-3-393-401 (In Russ).Садыкова Д.И., Лутфуллин И.Я. Первичная артериальная гипертензия и гипертрофия миокарда в детском и подростковом возрасте // Педиатрия. Журнал им. Г.Н. Сперанского. — 2009. — Т. 88. — № 5. — С. 16–21.Sadykova DI, Lutfullin IY. Primary arterial hypertension and myocardial hypertrophy in children and adolescents. Pediatria. Journal n.a. G.N. Speransky. 2009;88(5): 16–21. (In Russ).Vaduganathan M, Mensah GA, Turco JV, et al. The global burden of cardiovascular diseases and risk: a compass for future health. J Am Coll Cardiol. 2022;80(25):2361–2371. doi: https://doi.org/10.1016/j.jacc.2022.11.005Vaduganathan M, Mensah GA, Turco JV, et al. The global burden of cardiovascular diseases and risk: a compass for future health. J Am Coll Cardiol. 2022;80(25):2361–2371. doi: https://doi.org/10.1016/j.jacc.2022.11.005Gujral J, Gupta J. Pediatric Dyslipidemia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available online: https://www.ncbi.nlm.nih.gov/books/NBK585106. Accessed on July 28, 2022.Gujral J, Gupta J. Pediatric Dyslipidemia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available online: https://www.ncbi.nlm.nih.gov/books/NBK585106. Accessed on July 28, 2022.McGill HC Jr, McMahan CA, Malcom GT, et al. Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. The PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler Thromb Vasc Biol. 1997; 17(1):95–106. doi: https://doi.org/10.1161/01.atv.17.1.95McGill HC Jr, McMahan CA, Malcom GT, et al. Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. The PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler Thromb Vasc Biol. 1997; 17(1):95–106. doi: https://doi.org/10.1161/01.atv.17.1.95Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998;338(23):1650–1656. doi: https://doi.org/10.1056/NEJM199806043382302Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med. 1998;338(23):1650–1656. doi: https://doi.org/10.1056/NEJM199806043382302Ежов М.В., Бажан С.С., Ершова А. И. и др. Клинические рекомендации по семейной гиперхолестеринемии // Атеросклероз. — 2019. — Т. 15. — № 1. — С. 58–98.Ezhov MV, Bazhan SS, Ershova AI, et al. Clinical guidelines for familial hypercholesterolemia. Ateroscleroz. 2019;15(1):58–98. (In Russ).Di Taranto MD, Fortunato G. Genetic heterogeneity of Familial hypercholesterolemia: repercussions for molecular diagnosis. Int J Mol Sci. 2023;24(4):3224. doi: https://doi.org/10.3390/ijms24043224Di Taranto MD, Fortunato G. Genetic heterogeneity of Familial hypercholesterolemia: repercussions for molecular diagnosis. Int J Mol Sci. 2023;24(4):3224. doi: https://doi.org/10.3390/ijms24043224Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide prevalence of Familial hypercholesterolemia: meta-analyses of 11 million subjects. J Am Coll Cardiol. 2020;75(20):2553–2566. doi: https://doi.org/10.1016/j.jacc.2020.03.057Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide prevalence of Familial hypercholesterolemia: meta-analyses of 11 million subjects. J Am Coll Cardiol. 2020;75(20):2553–2566. doi: https://doi.org/10.1016/j.jacc.2020.03.057Toft-Nielsen F, Emanuelsson F, Benn M. Familial hypercholesterolemia prevalence among ethnicities-systematic review and meta-analysis. Front Genet. 2022;13:840797. doi: https://doi.org/10.3389/fgene.2022.840797Toft-Nielsen F, Emanuelsson F, Benn M. Familial hypercholesterolemia prevalence among ethnicities-systematic review and meta-analysis. Front Genet. 2022;13:840797. doi: https://doi.org/10.3389/fgene.2022.840797Mainieri F, Tagi VM, Chiarelli F. Recent advances on Familial Hypercholesterolemia in children and adolescents. Biomedicines. 2022;10(5):1043. doi: https://doi.org/10.3390/biomedicines10051043Mainieri F, Tagi VM, Chiarelli F. Recent advances on Familial Hypercholesterolemia in children and adolescents. Biomedicines. 2022;10(5):1043. doi: https://doi.org/10.3390/biomedicines10051043Wiegman A, Gidding SS, Watts GF, et al. Familial hyperc holesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36): 2425–2437. doi: https://doi.org/10.1093/eurheartj/ehv157Wiegman A, Gidding SS, Watts GF, et al. Familial hyperc holesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36): 2425–2437. doi: https://doi.org/10.1093/eurheartj/ehv157Чубыкина У.В., Ежов М.В., Рожкова Т.А. и др. Пятилетний период наблюдения за пациентами с гомо- и гетерозиготной семейной гиперхолестеринемией в регистре РЕНЕССАНС // Атеросклероз и дислипидемии. — 2023. — № 1. — С. 5–18. — doi: https://doi.org/10.34687/2219-8202.JAD.2023.01.0001Chubykina UV, Ezhov MV, Rozhkova TA, et al. A five-year follow-up period in homo and heterozygous familial hypercholesterolemia patients of the renaissance registry. Journal of atherosclerosis and dyslipidemias. 2023;(1):5–18. (In Russ). doi: https://doi.org/10.34687/2219-8202.JAD.2023.01.0001Леонтьева И.В. Семейная гомозиготная гиперхолестеринемия у детей: стратегия ранней диагностики и лечения // Российский вестник перинатологии и педиатрии. — 2021. — Т. 66. — № 4. — С. 118–128. — doi: https://doi.org/10.21508/10274065-2021-66-4-118-128Leontyeva IV. Familial homozygous hypercholesterolemia in children: early diagnosis and treatment. Rossijskij vestnik perinatologii i pediatrii = Russian Bulletin of Perinatology and Pediatrics. 2021;66(4):118–128. (In Russ). doi: https://doi.org/10.21508/1027-4065-2021-66-4-118-128Леонтьева И.В. Современная стратегия диагностики и лечения семейной гетерозиготной гиперхолестеринемии у детей // Российский вестник перинатологии и педиатрии. — 2020. — Т. 65. — № 4. — С. 27–40. — doi: https://doi.org/10.21508/1027-40652020-65-4-27-40Leontyeva IV. Modern strategy of diagnosis and treatment of children with heterozygous familial hypercholesterolemia. Rossijskij vestnik perinatologii i pediatrii = Russian Bulletin of Perinatology and Pediatrics. 2020;65(4):27–40. (In Russ). doi: https://doi.org/10.21508/1027-4065-2020-65-4-27-40Исаева А.С., Исакова Е.А. Генетические причины нарушений липидного обмена // Norwegian Journal of Development of the International Science. — 2018. — № 17-2. — С. 34–39.Isayeva A, Isakova Y. Genetic causes of lipid metabolism disorders. Norwegian Journal of Development of the International Science. 2018;(17-2): 34–39. (In Russ).Berberich AJ, Hegele RA. A modern approach to dyslipidemia. Endocr Rev. 2022;43(4):611–653. doi: https://doi.org/10.1210/endrev/bnab037Berberich AJ, Hegele RA. A modern approach to dyslipidemia. Endocr Rev. 2022;43(4):611–653. doi: https://doi.org/10.1210/endrev/bnab037Futema M, Taylor-Beadling A, Williams M, Humphries SE. Genetic testing for familial hypercholesterolemia-past, present, and future. J Lipid Res. 2021;62:100139. doi: https://doi.org/10.1016/j.jlr.2021.100139Futema M, Taylor-Beadling A, Williams M, Humphries SE. Genetic testing for familial hypercholesterolemia-past, present, and future. J Lipid Res. 2021;62:100139. doi: https://doi.org/10.1016/j.jlr.2021.100139Chora JR, Iacocca MA, Tichý L, et al. The clinical genome resource (clingen) familial hypercholesterolemia variant curation expert panel consensus guidelines for LDLR variant classification. Genet Med. 2022;24(2):293–306. doi: https://doi.org/10.1016/j.gim.2021.09.012Chora JR, Iacocca MA, Tichý L, et al. The clinical genome resource (clingen) familial hypercholesterolemia variant curation expert panel consensus guidelines for LDLR variant classification. Genet Med. 2022;24(2):293–306. doi: https://doi.org/10.1016/j.gim.2021.09.012Futema M, Ramaswami U, Tichy L, et al. Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. Atherosclerosis. 2021;319:108–117. doi: https://doi.org/10.1016/j.atherosclerosis.2021.01.008Futema M, Ramaswami U, Tichy L, et al. Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries. Atherosclerosis. 2021;319:108–117. doi: https://doi.org/10.1016/j.atherosclerosis.2021.01.008Abou Khalil Y, Marmontel O, Ferrières J, et al. APOE molecular spectrum in a French cohort with primary dyslipidemia. Int J Mol Sci. 2022;23(10):5792. doi: https://doi.org/10.3390/ijms23105792Abou Khalil Y, Marmontel O, Ferrières J, et al. APOE molecular spectrum in a French cohort with primary dyslipidemia. Int J Mol Sci. 2022;23(10):5792. doi: https://doi.org/10.3390/ijms23105792Cao YX, Sun D, Liu HH, et al. Improvement of definite diagnosis of familial hypercholesterolemia using an expanding genetic analysis. JACC Asia. 2021;1(1):82–89. doi: https://doi.org/10.1016/j.jacasi.2021.04.001Cao YX, Sun D, Liu HH, et al. Improvement of definite diagnosis of familial hypercholesterolemia using an expanding genetic analysis. JACC Asia. 2021;1(1):82–89. doi: https://doi.org/10.1016/j.jacasi.2021.04.001Loaiza N, Hartgers ML, Reeskamp LF, et al. Taking one step back in familial hypercholesterolemia: STAP1 does not alter plasma LDL (Low-Density Lipoprotein) cholesterol in mice and humans. Arterioscler Thromb Vasc Biol. 2020;40(4):973–985. doi: https://doi.org/10.1161/ATVBAHA.119.313470Loaiza N, Hartgers ML, Reeskamp LF, et al. Taking one step back in familial hypercholesterolemia: STAP1 does not alter plasma LDL (Low-Density Lipoprotein) cholesterol in mice and humans. Arterioscler Thromb Vasc Biol. 2020;40(4):973–985. doi: https://doi.org/10.1161/ATVBAHA.119.313470Tada H, Kawashiri MA, Nomura A, et al. Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery disease. J Clin Lipidol. 2018;(6):1436–1444. doi: https://doi.org/10.1016/j.jacl.2018.08.006Tada H, Kawashiri MA, Nomura A, et al. Oligogenic familial hypercholesterolemia, LDL cholesterol, and coronary artery disease. J Clin Lipidol. 2018;(6):1436–1444. doi: https://doi.org/10.1016/j.jacl.2018.08.006Nishikawa R, Furuhashi M, Hori M, et al. A resuscitated case of acute myocardial infarction with both familial hypercholesterolemia phenotype caused by possibly oligogenic variants of the PCSK9 and ABCG5 genes and type I CD36 deficiency. J Atheroscler Thromb. 2022; 29(4):551–557. doi: https://doi.org/10.5551/jat.58909Nishikawa R, Furuhashi M, Hori M, et al. A resuscitated case of acute myocardial infarction with both familial hypercholesterolemia phenotype caused by possibly oligogenic variants of the PCSK9 and ABCG5 genes and type I CD36 deficiency. J Atheroscler Thromb. 2022; 29(4):551–557. doi: https://doi.org/10.5551/jat.58909Paquette M, Fantino M, Bernard S, Baass A. Paternal inheritance predicts earlier cardiovascular event onset in patients with familial hypercholesterolemia. Atherosclerosis. 2021;329:9–13. doi: https://doi.org/10.1016/j.atherosclerosis.2021.06.006Paquette M, Fantino M, Bernard S, Baass A. Paternal inheritance predicts earlier cardiovascular event onset in patients with familial hypercholesterolemia. Atherosclerosis. 2021;329:9–13. doi: https://doi.org/10.1016/j.atherosclerosis.2021.06.006Mourre F, Giorgi R, Gallo A, et al. Maternal inheritance of familial hypercholesterolemia gene mutation predisposes to coronary atherosclerosis as assessed by calcium score in adulthood. Arterioscler Thromb Vasc Biol. 2023;43(2):94–103. doi: https://doi.org/10.1161/ATVBAHA.122.318119Mourre F, Giorgi R, Gallo A, et al. Maternal inheritance of familial hypercholesterolemia gene mutation predisposes to coronary atherosclerosis as assessed by calcium score in adulthood. Arterioscler Thromb Vasc Biol. 2023;43(2):94–103. doi: https://doi.org/10.1161/ATVBAHA.122.318119Abdul-Razak S, Rahmat R, Mohd Kasim A, et al. Diagnostic performance of various familial hypercholesterolaemia diagnostic criteria compared to Dutch lipid clinic criteria in an Asian population. BMC Cardiovasc Disord. 2017;17(1):264. doi: https://doi.org/10.1186/s12872-017-0694-zAbdul-Razak S, Rahmat R, Mohd Kasim A, et al. Diagnostic performance of various familial hypercholesterolaemia diagnostic criteria compared to Dutch lipid clinic criteria in an Asian population. BMC Cardiovasc Disord. 2017;17(1):264. doi: https://doi.org/10.1186/s12872-017-0694-zAl-Rasadi K, Al-Waili K, Al-Sabti HA, et al. Criteria for Diagnosis of Familial Hypercholesterolemia: A Comprehensive Analysis of the Different Guidelines, Appraising their Suitability in the Omani Arab Population. Oman Med J. 2014;29(2):85–91. doi: https://doi.org/10.5001/omj.2014.22Al-Rasadi K, Al-Waili K, Al-Sabti HA, et al. Criteria for Diagnosis of Familial Hypercholesterolemia: A Comprehensive Analysis of the Different Guidelines, Appraising their Suitability in the Omani Arab Population. Oman Med J. 2014;29(2):85–91. doi: https://doi.org/10.5001/omj.2014.22Ежов М.В., Сергиенко И.В., Рожкова Т.А. и др. Российские рекомендации по диагностике и лечению семейной гиперхолестеринемии // Атеросклероз и дислипидемии. — 2016. — № 4. — С. 21–29.Ezhov MV, Sergienko IV, Rozhkova TA, et al. Russian Guidelines on Familial Hypercholesterolemia Diagnosis and Treatment. Journal of atherosclerosis and dyslipidemias. 2016;(4):21–29. (In Russ).Садыкова Д.И., Галимова Л.Ф., Леонтьева И.В., Сластникова Е.С. Оценка толщины комплекса интима-медиа у детей с семейной гиперхолестеринемией // Российский вестник перинатологии и педиатрии. — 2018. — Т. 63. — № 5. — С. 152–154. — doi: https://doi.org/10.21508/1027-4065-2018-63-5-152-154Sadykova DI, Galimova LF, Leontyeva IV, Slastnikova ES. Estimation of the thickness of the intima-media complex in children with familial hypercholesterolemia. Rossiyskiy Vestnik Perinatologii i Pediatrii = Russian Bulletin of Perinatology and Pediatrics. 2018;63(5): 152–154. (In Russ). doi: https://doi.org/10.21508/1027-40652018-63-5-152-154Kusters DM, Wiegman A, Kastelein JJ, Hutten BA. Carotid intimamedia thickness in children with familial hypercholesterolemia. Circ Res. 2014;114(2):307–310. doi: https://doi.org/10.1161/CIRCRESAHA.114.301430Kusters DM, Wiegman A, Kastelein JJ, Hutten BA. Carotid intimamedia thickness in children with familial hypercholesterolemia. Circ Res. 2014;114(2):307–310. doi: https://doi.org/10.1161/CIRCRESAHA.114.301430Pan J, Liu J, Wang H, et al. Association of carotid atherosclerosis with lipid components in asymptomatic low-income Chinese: a population-based cross-sectional study. Front Neurol. 2020;11: 276. doi: https://doi.org/10.3389/fneur.2020.00276Pan J, Liu J, Wang H, et al. Association of carotid atherosclerosis with lipid components in asymptomatic low-income Chinese: a population-based cross-sectional study. Front Neurol. 2020;11: 276. doi: https://doi.org/10.3389/fneur.2020.00276Gidding SS, Wiegman A, Groselj U, et al. Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendations. Eur J Prev Cardiol. 2022;29(18): 2301–2311. doi: https://doi.org/10.1093/eurjpc/zwac200Gidding SS, Wiegman A, Groselj U, et al. Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendations. Eur J Prev Cardiol. 2022;29(18): 2301–2311. doi: https://doi.org/10.1093/eurjpc/zwac200Schefelker JM, Peterson AL. Screening and management of dyslipidemia in children and adolescents. J Clin Med. 2022; 11(21):6479. doi: https://doi.org/10.3390/jcm11216479Schefelker JM, Peterson AL. Screening and management of dyslipidemia in children and adolescents. J Clin Med. 2022; 11(21):6479. doi: https://doi.org/10.3390/jcm11216479Šuštar U, Mlinarič M, Kovač J, et al. Universal screening is an effective strategy for detecting patients with Familial Hypercholesterolemia. Atherosclerosis. 2022;355:7. doi: https://doi.org/10.1016/j.atherosclerosis.2022.06.021Šuštar U, Mlinarič M, Kovač J, et al. Universal screening is an effective strategy for detecting patients with Familial Hypercholesterolemia. Atherosclerosis. 2022;355:7. doi: https://doi.org/10.1016/j.atherosclerosis.2022.06.021Alonso R, Perez de Isla L, Muñiz-Grijalvo O, Mata P. Barriers to early diagnosis and treatment of familial hypercholesterolemia: current perspectives on improving patient care. Vasc Health Risk Manag. 2020;16:11–25. doi: https://doi.org/10.2147/VHRM.S192401Alonso R, Perez de Isla L, Muñiz-Grijalvo O, Mata P. Barriers to early diagnosis and treatment of familial hypercholesterolemia: current perspectives on improving patient care. Vasc Health Risk Manag. 2020;16:11–25. doi: https://doi.org/10.2147/VHRM.S192401Галимова Л.Ф., Садыкова Д.И., Сластникова Е.С., Усова Н.Э. Диагностика семейной гиперхолестеринемии у детей: каскадный скрининг от теории к практике // Кардиоваскулярная терапия и профилактика. — 2020. — Т. 19. — № 3. — С. 191–196. — doi: https://doi.org/10.15829/1728-8800-2020-2348Galimova LF, Sadykova DI, Slastnikova ES, Usova NE. Diagnosis of familial hypercholesterolemia in children: cascade screening from theory to practice. Cardiovascular Therapy and Prevention. 2020;19(3):191–196. (In Russ). doi: https://doi.org/10.15829/1728-8800-2020-2348Groselj U, Kovac J, Sustar U, et al. Universal screening for familial hypercholesterolemia in children: The Slovenian model and literature review. Atherosclerosis. 2018;277:383–391. doi: https://doi.org/10.1016/j.atherosclerosis.2018.06.858Groselj U, Kovac J, Sustar U, et al. Universal screening for familial hypercholesterolemia in children: The Slovenian model and literature review. Atherosclerosis. 2018;277:383–391. doi: https://doi.org/10.1016/j.atherosclerosis.2018.06.858Medeiros AM, Bourbon M. Genetic testing in familial hypercholesterolemia: is it for everyone? Curr Atheroscler Rep. 2023;25(4): 127–132. doi: https://doi.org/10.1007/s11883-023-01091-5Medeiros AM, Bourbon M. Genetic testing in familial hypercholesterolemia: is it for everyone? Curr Atheroscler Rep. 2023;25(4): 127–132. doi: https://doi.org/10.1007/s11883-023-01091-5Sanin V, Schmieder R, Ates S, et al. Population-based screening in children for early diagnosis and treatment of familial hypercholesterolemia: design of the VRONI study. Eur J Public Health. 2022; 32(3):422–428. doi: https://doi.org/10.1093/eurpub/ckac007Sanin V, Schmieder R, Ates S, et al. Population-based screening in children for early diagnosis and treatment of familial hypercholesterolemia: design of the VRONI study. Eur J Public Health. 2022; 32(3):422–428. doi: https://doi.org/10.1093/eurpub/ckac007Lazaro P, Perez de Isla L, Watts GF, et al. Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia. J Clin Lipidol. 2017;11(1):260–271. doi: https://doi.org/10.1016/j.jacl.2017.01.002Lazaro P, Perez de Isla L, Watts GF, et al. Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia. J Clin Lipidol. 2017;11(1):260–271. doi: https://doi.org/10.1016/j.jacl.2017.01.002Louter L, Defesche J, Roeters van Lennep J. Cascade screening for familial hypercholesterolemia: Practical consequences. Atheroscler Suppl. 2017;30:77–85. doi: https://doi.org/10.1016/j.atherosclerosissup.2017.05.019Louter L, Defesche J, Roeters van Lennep J. Cascade screening for familial hypercholesterolemia: Practical consequences. Atheroscler Suppl. 2017;30:77–85. doi: https://doi.org/10.1016/j.atherosclerosissup.2017.05.019Vanhoye X, Bardel C, Rimbert A, et al. A new 165-SNP lowdensity lipoprotein cholesterol polygenic risk score based on next generation sequencing outperforms previously published scores in routine diagnostics of familial hypercholesterolemia. Transl Res. 2022;22:1931. doi: https://doi.org/10.1016/j.trsl.2022.12.002Vanhoye X, Bardel C, Rimbert A, et al. A new 165-SNP lowdensity lipoprotein cholesterol polygenic risk score based on next generation sequencing outperforms previously published scores in routine diagnostics of familial hypercholesterolemia. Transl Res. 2022;22:1931. doi: https://doi.org/10.1016/j.trsl.2022.12.002Lima IR, Tada MT, Oliveira TGM, et al. Polygenic risk score for hypercholesterolemia in a Brazilian familial hypercholesterolemia cohort. Atheroscler Plus. 2022;49:47–55. doi: https://doi.org/10.1016/j.athplu.2022.06.002Lima IR, Tada MT, Oliveira TGM, et al. Polygenic risk score for hypercholesterolemia in a Brazilian familial hypercholesterolemia cohort. Atheroscler Plus. 2022;49:47–55. doi: https://doi.org/10.1016/j.athplu.2022.06.002Tandirerung FJ. The clinical importance of differentiating monogenic familial hypercholesterolemia from polygenic hypercholesterolemia. Curr Cardiol Rep. 2022;24(11):1669–1677. doi: https://doi.org/10.1007/s11886-022-01783-5Tandirerung FJ. The clinical importance of differentiating monogenic familial hypercholesterolemia from polygenic hypercholesterolemia. Curr Cardiol Rep. 2022;24(11):1669–1677. doi: https://doi.org/10.1007/s11886-022-01783-5Martin AC, Gidding SS, Wiegman A, et al. Knowns and unknowns in the care of pediatric familial hypercholesterolemia. J Lipid Res. 2017;58(9):1765–1776. doi: https://doi.org/10.1194/jlr.S074039Martin AC, Gidding SS, Wiegman A, et al. Knowns and unknowns in the care of pediatric familial hypercholesterolemia. J Lipid Res. 2017;58(9):1765–1776. doi: https://doi.org/10.1194/jlr.S074039Lampropoulou M, Chaini M, Rigopoulos R, et al. Association between serum lipid levels in Greek children with dyslipidemia and Mediterranean diet adherence, dietary habits, lifestyle and family socioeconomic factors. Nutrients. 2020;12(6):1–15. doi: https://doi.org/10.3390/nu12061600Lampropoulou M, Chaini M, Rigopoulos R, et al. Association between serum lipid levels in Greek children with dyslipidemia and Mediterranean diet adherence, dietary habits, lifestyle and family socioeconomic factors. Nutrients. 2020;12(6):1–15. doi: https://doi.org/10.3390/nu12061600Hui L, Kwok ME, Nelson AE, et al. Breastfeeding in infancy and lipid profile in adolescence. Pediatrics. 2019;143(5):1–8. doi: https://doi.org/10.1542/peds.2018-3075Hui L, Kwok ME, Nelson AE, et al. Breastfeeding in infancy and lipid profile in adolescence. Pediatrics. 2019;143(5):1–8. doi: https://doi.org/10.1542/peds.2018-3075Williams LA, Wilson DP. Nutritional management of pediatric dyslipidemia. In: Endotext [Internet]. South Dartmouth (MA): MDText. com, Inc.; 2000. Available online: https://www.ncbi.nlm.nih.gov/books/NBK395582. Accessed on November 01, 2022.Williams LA, Wilson DP. Nutritional management of pediatric dyslipidemia. In: Endotext [Internet]. South Dartmouth (MA): MDText. com, Inc.; 2000. Available online: https://www.ncbi.nlm.nih.gov/books/NBK395582. Accessed on November 01, 2022.De Jesus JM. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128(Suppl 5):S213–S256. doi: https://doi.org/10.1542/peds.2009-2107CDe Jesus JM. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128(Suppl 5):S213–S256. doi: https://doi.org/10.1542/peds.2009-2107CFiorentino R, Chiarelli F. Treatment of dyslipidaemia in children. Biomedicines. 2021;9(9):1078. doi: https://doi.org/10.3390/biomedicines9091078Fiorentino R, Chiarelli F. Treatment of dyslipidaemia in children. Biomedicines. 2021;9(9):1078. doi: https://doi.org/10.3390/biomedicines9091078Yu-Poth S, Zhao G, Etherton T, et al. Effects of the National Cholesterol Education Program’s Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. Am J Clin Nutr. 1999;69(4):632–646. doi: https://doi.org/10.1093/ajcn/69.4.632Yu-Poth S, Zhao G, Etherton T, et al. Effects of the National Cholesterol Education Program’s Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. Am J Clin Nutr. 1999;69(4):632–646. doi: https://doi.org/10.1093/ajcn/69.4.632Simell O, Niinikoski H, Rönnemaa T, et al. Cohort Profile: the STRIP Study (Special Turku Coronary Risk Factor Intervention Project), an Infancy-onset Dietary and Life-style Intervention Trial. Int J Epidemiol. 2009;38(3):650–655. doi: https://doi.org/10.1093/ije/dyn072Simell O, Niinikoski H, Rönnemaa T, et al. Cohort Profile: the STRIP Study (Special Turku Coronary Risk Factor Intervention Project), an Infancy-onset Dietary and Life-style Intervention Trial. Int J Epidemiol. 2009;38(3):650–655. doi: https://doi.org/10.1093/ije/dyn072Manousaki D, Barnett TA, Mathieu ME, et al. Tune out and turn in: the influence of television viewing and sleep on lipid profiles in children. Int J Obes (Lond). 2020;44(5):1173–1184. doi: https://doi.org/10.1038/s41366-020-0527-5Manousaki D, Barnett TA, Mathieu ME, et al. Tune out and turn in: the influence of television viewing and sleep on lipid profiles in children. Int J Obes (Lond). 2020;44(5):1173–1184. doi: https://doi.org/10.1038/s41366-020-0527-5Langslet G, Johansen AK, Bogsrud MP, et al. Thirty percent of children and young adults with familial hypercholesterolemia treated with statins have adherence issues. Am J Prev Cardiol. 2021;6: 100180. doi: https://doi.org/10.1016/j.ajpc.2021.100180Langslet G, Johansen AK, Bogsrud MP, et al. Thirty percent of children and young adults with familial hypercholesterolemia treated with statins have adherence issues. Am J Prev Cardiol. 2021;6: 100180. doi: https://doi.org/10.1016/j.ajpc.2021.100180Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev. 2019;11:CD006401. doi: https://doi.org/10.1002/14651858.CD006401.pub5Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev. 2019;11:CD006401. doi: https://doi.org/10.1002/14651858.CD006401.pub5Tada H, Takamura M, Kawashiri M. Familial Hypercholesterolemia: a narrative review on diagnosis and management strategies for children and adolescents. Vasc Health Risk Manag. 2021;17: 59–67. doi: https://doi.org/10.2147/VHRM.S266249Tada H, Takamura M, Kawashiri M. Familial Hypercholesterolemia: a narrative review on diagnosis and management strategies for children and adolescents. Vasc Health Risk Manag. 2021;17: 59–67. doi: https://doi.org/10.2147/VHRM.S266249Anagnostis P, Vaitsi K, Kleitsioti P, et al. Efficacy and safety of statin use in children and adolescents with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized-controlled trials. Endocrine. 2020;69(2):249–261. doi: https://doi.org/10.1007/s12020-020-02302-8Anagnostis P, Vaitsi K, Kleitsioti P, et al. Efficacy and safety of statin use in children and adolescents with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized-controlled trials. Endocrine. 2020;69(2):249–261. doi: https://doi.org/10.1007/s12020-020-02302-8Braamskamp M, Langslet G, McCrindle BW, et al. Effect of rosuvastatin on carotid intima-media thickness in children with heterozygous familial hypercholesterolemia: The CHARON study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label). Circulation. 2017;136(4):359–366. doi: https://doi.org/10.1161/CIRCULATIONAHA.116.025158Braamskamp M, Langslet G, McCrindle BW, et al. Effect of rosuvastatin on carotid intima-media thickness in children with heterozygous familial hypercholesterolemia: The CHARON study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label). Circulation. 2017;136(4):359–366. doi: https://doi.org/10.1161/CIRCULATIONAHA.116.025158Mytilinaiou M, Kyrou I, Khan M, et al. Familial Hypercholesterolemia: new horizons for diagnosis and effective management. Front Pharmacol. 2018;9:1–29. doi: https://doi.org/10.3389/fphar.2018.00707Mytilinaiou M, Kyrou I, Khan M, et al. Familial Hypercholesterolemia: new horizons for diagnosis and effective management. Front Pharmacol. 2018;9:1–29. doi: https://doi.org/10.3389/fphar.2018.00707Alonso R, Muñiz-Grijalvo O, Díaz-Díaz JL, et al. Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience. J Clin Lipidol. 2021;15(4):584–592. doi: https://doi.org/10.1016/j.jacl.2021.04.011Alonso R, Muñiz-Grijalvo O, Díaz-Díaz JL, et al. Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience. J Clin Lipidol. 2021;15(4):584–592. doi: https://doi.org/10.1016/j.jacl.2021.04.011Santos RD, Ruzza A, Hovingh GK, et al. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020;383(14):1317–1327. doi: https://doi.org/10.1056/NEJMoa2019910Santos RD, Ruzza A, Hovingh GK, et al. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020;383(14):1317–1327. doi: https://doi.org/10.1056/NEJMoa2019910Ito MK, Sanros RD. PCSK9 Inhibition with monoclonal antibodies: modern management of hypercholesterolemia. J Clin Pharmacol. 2017;57(1):7–32. doi: https://doi.org/10.1002/jcph.766Ito MK, Sanros RD. PCSK9 Inhibition with monoclonal antibodies: modern management of hypercholesterolemia. J Clin Pharmacol. 2017;57(1):7–32. doi: https://doi.org/10.1002/jcph.766Lee CJ, Yoon M, Kang HJ, et al. 2022 Consensus statement on the management of familial hypercholesterolemia in Korea. Korean J Intern Med. 2022;37(5):931–944. doi: https://doi.org/10.3904/kjim.2022.121Lee CJ, Yoon M, Kang HJ, et al. 2022 Consensus statement on the management of familial hypercholesterolemia in Korea. Korean J Intern Med. 2022;37(5):931–944. doi: https://doi.org/10.3904/kjim.2022.121Erasmo L, Cefalu AB, Noto D, et al. Efficacy of lomitapide in the treatment of Familial Homozygous hypercholesterolemia: Results of a Real-World Clinical Experience in Italy. Adv Ther. 2017;34(5):1200–1210. doi: https://doi.org/10.1007/s12325017-0531-xErasmo L, Cefalu AB, Noto D, et al. Efficacy of lomitapide in the treatment of Familial Homozygous hypercholesterolemia: Results of a Real-World Clinical Experience in Italy. Adv Ther. 2017;34(5):1200–1210. doi: https://doi.org/10.1007/s12325017-0531-xBen-Omran T, Masana L, Kolovou G, et al. Real-World outcomes with lomitapide use in pediatric patients with homozygous familial hypercholesterolaemia. Adv Ther. 2019;36(7):1786–1811. doi: https://doi.org/10.1007/s12325-019-00985-8Ben-Omran T, Masana L, Kolovou G, et al. Real-World outcomes with lomitapide use in pediatric patients with homozygous familial hypercholesterolaemia. Adv Ther. 2019;36(7):1786–1811. doi: https://doi.org/10.1007/s12325-019-00985-8Visser ME, Akdim F, Tribble DL, et al. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res. 2010;51(5):1057–1062. doi: https://doi.org/10.1194/jlr.M002915Visser ME, Akdim F, Tribble DL, et al. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res. 2010;51(5):1057–1062. doi: https://doi.org/10.1194/jlr.M002915Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383(8):711–720. doi: https://doi.org/10.1056/NEJMoa2004215Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383(8):711–720. doi: https://doi.org/10.1056/NEJMoa2004215Hermel M, Lieberman M, Slipczuk L, et al. Monoclonal antibodies, gene silencing and gene editing (CRISPR) therapies for the treatment of hyperlipidemia-the future is here. Pharmaceutics. 2023;15(2):459. doi: https://doi.org/10.3390/pharmaceutics15020459Hermel M, Lieberman M, Slipczuk L, et al. Monoclonal antibodies, gene silencing and gene editing (CRISPR) therapies for the treatment of hyperlipidemia-the future is here. Pharmaceutics. 2023;15(2):459. doi: https://doi.org/10.3390/pharmaceutics15020459Roch VZ, Santos R. Past, Present, and future of Familial Hypercholesterolemia management. Methodist Debakey Cardiovasc J. 2021;17(4):28–35. doi: https://doi.org/10.14797/mdcvj.887Roch VZ, Santos R. Past, Present, and future of Familial Hypercholesterolemia management. Methodist Debakey Cardiovasc J. 2021;17(4):28–35. doi: https://doi.org/10.14797/mdcvj.887Tomlinson B, Patil NG, Fok M, et al. Role of PCSK9 Inhibitors in patients with Familial Hypercholesterolemia. Endocrinol Metab (Seoul). 2021;36(2):279–295. doi: https://doi.org/10.3803/EnM.2021.964Tomlinson B, Patil NG, Fok M, et al. Role of PCSK9 Inhibitors in patients with Familial Hypercholesterolemia. Endocrinol Metab (Seoul). 2021;36(2):279–295. doi: https://doi.org/10.3803/EnM.2021.964Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020:16;382(16):1520–1530. doi: https://doi.org/10.1056/NEJMoa1913805Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020:16;382(16):1520–1530. doi: https://doi.org/10.1056/NEJMoa1913805Reijman MD, Schweizer A, Peterson ALH, et al. Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia. Eur J Prev Cardiol. 2022;29(9):1361–1368. doi: https://doi.org/10.1093/eurjpc/zwac025Reijman MD, Schweizer A, Peterson ALH, et al. Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia. Eur J Prev Cardiol. 2022;29(9):1361–1368. doi: https://doi.org/10.1093/eurjpc/zwac025Ishigaki Y, Kawagishi N, Hasegawa Y, et al. Liver transplantation for homozygous familial hypercholesterolemia. J Atheroscler Thromb. 2019;26(2):121–127. doi: https://doi.org/10.5551/jat.RV17029Ishigaki Y, Kawagishi N, Hasegawa Y, et al. Liver transplantation for homozygous familial hypercholesterolemia. J Atheroscler Thromb. 2019;26(2):121–127. doi: https://doi.org/10.5551/jat.RV17029Björkegren JLM, Lusis AJ. Atherosclerosis: Recent developments. Cell. 2022;185(10):1630–1645. doi: https://doi.org/10.1016/j.cell.2022.04.004Björkegren JLM, Lusis AJ. Atherosclerosis: Recent developments. Cell. 2022;185(10):1630–1645. doi: https://doi.org/10.1016/j.cell.2022.04.004Berta E, Zsiros N, Bodor M, et al. Clinical aspects of genetic and non-genetic cardiovascular risk factors in familial hypercholesterolemia. Genes. 2022;13(7):1–19. doi: https://doi.org/10.3390/genes13071158Berta E, Zsiros N, Bodor M, et al. Clinical aspects of genetic and non-genetic cardiovascular risk factors in familial hypercholesterolemia. Genes. 2022;13(7):1–19. doi: https://doi.org/10.3390/genes13071158Braamskamp MJ, Kusters DM, Avis HJ, et al. Patients with familial hypercholesterolemia who initiated statin treatment in childhood are at lower risk for CHD then their affected parents. Circulation. 2013;128(Suppl 22):A17837.Braamskamp MJ, Kusters DM, Avis HJ, et al. Patients with familial hypercholesterolemia who initiated statin treatment in childhood are at lower risk for CHD then their affected parents. Circulation. 2013;128(Suppl 22):A17837.Kesavan G. Innovations in CRISPR-Based Therapies. Mol Biotechnol. 2023;65(2):138–145. doi: https://doi.org/10.1007/s12033-021-00411-xKesavan G. Innovations in CRISPR-Based Therapies. Mol Biotechnol. 2023;65(2):138–145. doi: https://doi.org/10.1007/s12033-021-00411-xAsmamaw M, Zawdie B. Mechanism and applications of CRISPR/ Cas-9-Mediated Genome Editing. Biologics. 2021;15:353–361. doi: https://doi.org/10.2147/BTT.S326422Asmamaw M, Zawdie B. Mechanism and applications of CRISPR/ Cas-9-Mediated Genome Editing. Biologics. 2021;15:353–361. doi: https://doi.org/10.2147/BTT.S326422Alnouri F, Santos RD. New trends and therapies for familial hypercholesterolemia. J Clin Med. 2022;11(22):6638. doi: https://doi.org/10.3390/jcm11226638Alnouri F, Santos RD. New trends and therapies for familial hypercholesterolemia. J Clin Med. 2022;11(22):6638. doi: https://doi.org/10.3390/jcm11226638Zhao H, Li Y, He L, et al. In Vivo AAV-CRISPR/Cas9-mediated gene editing ameliorates atherosclerosis in familial hypercholesterolemia. Circulation. 2020;141(1):67–79. doi: https://doi.org/10.1161/CIRCULATIONAHA.119.042476Zhao H, Li Y, He L, et al. In Vivo AAV-CRISPR/Cas9-mediated gene editing ameliorates atherosclerosis in familial hypercholesterolemia. Circulation. 2020;141(1):67–79. doi: https://doi.org/10.1161/CIRCULATIONAHA.119.042476Močnik M, Marčun Varda N. Lipid biomarkers and atherosclerosisold and new in cardiovascular risk in childhood. Int J Mol Sci. 2023; 24(3):2237. doi: https://doi.org/10.3390/ijms24032237Močnik M, Marčun Varda N. Lipid biomarkers and atherosclerosisold and new in cardiovascular risk in childhood. Int J Mol Sci. 2023; 24(3):2237. doi: https://doi.org/10.3390/ijms24032237Fricaudet M, Di-Filippo, Mouli P, et al. Performance assessment of salivary screening in familial hypercholesterolemia in children. Atherosclerosis. 2021;331:E183. doi: https://doi.org/10.1016/j.atherosclerosis.2021.06.558Fricaudet M, Di-Filippo, Mouli P, et al. Performance assessment of salivary screening in familial hypercholesterolemia in children. Atherosclerosis. 2021;331:E183. doi: https://doi.org/10.1016/j.atherosclerosis.2021.06.558

The authors declare that there are no conflicts of interest present.